David F. Moreno , Albert Oriol , Javier de la Rubia , Miguel T. Hernández , María Belén Iñigo , Luis Palomera , Felipe de Arriba , Yolanda González , Ana Isabel Teruel , Jordi López Pardo , Ana López de la Guía , Antonia Sampol , Rafael Ríos-Tamayo , Anna Sureda , Norma C. Gutiérrez , Maria-Jose Calasanz , María Luisa Martín Ramos , María Victoria Mateos , Jesús San Miguel , Juan José Lahuerta , Laura Rosiñol
{"title":"t（11;14）总是标准风险细胞遗传学异常吗？GEM05MENOS65和GEM2012 PETHEMA/GEM移植试验结果。","authors":"David F. Moreno , Albert Oriol , Javier de la Rubia , Miguel T. Hernández , María Belén Iñigo , Luis Palomera , Felipe de Arriba , Yolanda González , Ana Isabel Teruel , Jordi López Pardo , Ana López de la Guía , Antonia Sampol , Rafael Ríos-Tamayo , Anna Sureda , Norma C. Gutiérrez , Maria-Jose Calasanz , María Luisa Martín Ramos , María Victoria Mateos , Jesús San Miguel , Juan José Lahuerta , Laura Rosiñol","doi":"10.1016/j.clml.2025.01.014","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Recent studies describe inferior outcomes in newly diagnosed multiple myeloma (NDMM) patients with t(11;14) treated with novel agents.</div></div><div><h3>Materials and methods</h3><div>We analyzed 240 NDMM transplant eligible (TE) patients who received triplet induction regimen in the GEM05MENOS65 (bortezomib, thalidomide and dexamethasone – VTD) and GEM2012 (bortezomib, lenalidomide and dexamethasone – VRD) clinical trials.</div></div><div><h3>Results</h3><div>t(11;14) and standard risk (SR) non-t(11;14) were prevalent in 51 (21%) and 189 (79%) patients, respectively. Patients with t(11;14) treated with VTD had a lower overall response rate (ORR) (84% vs. 97%, <em>P</em> = .044) and lower negative minimal residual disease (MRD) (7.7% vs 35.1%, <em>P</em> = .049) after induction, as compared to SR non-t(11;14), while there were no differences in ORR (87% vs. 89%) or negative MRD (13.2% vs. 24.4%, <em>P</em> = .2) for these 2 subgroups in patients treated with VRD. The presence of t(11;14) impacted negatively on PFS in patients with VTD (hazard ratio 2.70; <em>P</em> = .005), while no differences were observed in those treated with VRD.</div></div><div><h3>Conclusion</h3><div>TE NDMM patients harboring t(11;14) had an inferior outcome compared with SR patients when receiving induction therapy with VTD while no differences were observed when receiving a lenalidomide containing regimen.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 494-504"},"PeriodicalIF":4.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials\",\"authors\":\"David F. Moreno , Albert Oriol , Javier de la Rubia , Miguel T. Hernández , María Belén Iñigo , Luis Palomera , Felipe de Arriba , Yolanda González , Ana Isabel Teruel , Jordi López Pardo , Ana López de la Guía , Antonia Sampol , Rafael Ríos-Tamayo , Anna Sureda , Norma C. Gutiérrez , Maria-Jose Calasanz , María Luisa Martín Ramos , María Victoria Mateos , Jesús San Miguel , Juan José Lahuerta , Laura Rosiñol\",\"doi\":\"10.1016/j.clml.2025.01.014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Recent studies describe inferior outcomes in newly diagnosed multiple myeloma (NDMM) patients with t(11;14) treated with novel agents.</div></div><div><h3>Materials and methods</h3><div>We analyzed 240 NDMM transplant eligible (TE) patients who received triplet induction regimen in the GEM05MENOS65 (bortezomib, thalidomide and dexamethasone – VTD) and GEM2012 (bortezomib, lenalidomide and dexamethasone – VRD) clinical trials.</div></div><div><h3>Results</h3><div>t(11;14) and standard risk (SR) non-t(11;14) were prevalent in 51 (21%) and 189 (79%) patients, respectively. Patients with t(11;14) treated with VTD had a lower overall response rate (ORR) (84% vs. 97%, <em>P</em> = .044) and lower negative minimal residual disease (MRD) (7.7% vs 35.1%, <em>P</em> = .049) after induction, as compared to SR non-t(11;14), while there were no differences in ORR (87% vs. 89%) or negative MRD (13.2% vs. 24.4%, <em>P</em> = .2) for these 2 subgroups in patients treated with VRD. The presence of t(11;14) impacted negatively on PFS in patients with VTD (hazard ratio 2.70; <em>P</em> = .005), while no differences were observed in those treated with VRD.</div></div><div><h3>Conclusion</h3><div>TE NDMM patients harboring t(11;14) had an inferior outcome compared with SR patients when receiving induction therapy with VTD while no differences were observed when receiving a lenalidomide containing regimen.</div></div>\",\"PeriodicalId\":10348,\"journal\":{\"name\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"volume\":\"25 7\",\"pages\":\"Pages 494-504\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2152265025000242\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265025000242","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials
Purpose
Recent studies describe inferior outcomes in newly diagnosed multiple myeloma (NDMM) patients with t(11;14) treated with novel agents.
Materials and methods
We analyzed 240 NDMM transplant eligible (TE) patients who received triplet induction regimen in the GEM05MENOS65 (bortezomib, thalidomide and dexamethasone – VTD) and GEM2012 (bortezomib, lenalidomide and dexamethasone – VRD) clinical trials.
Results
t(11;14) and standard risk (SR) non-t(11;14) were prevalent in 51 (21%) and 189 (79%) patients, respectively. Patients with t(11;14) treated with VTD had a lower overall response rate (ORR) (84% vs. 97%, P = .044) and lower negative minimal residual disease (MRD) (7.7% vs 35.1%, P = .049) after induction, as compared to SR non-t(11;14), while there were no differences in ORR (87% vs. 89%) or negative MRD (13.2% vs. 24.4%, P = .2) for these 2 subgroups in patients treated with VRD. The presence of t(11;14) impacted negatively on PFS in patients with VTD (hazard ratio 2.70; P = .005), while no differences were observed in those treated with VRD.
Conclusion
TE NDMM patients harboring t(11;14) had an inferior outcome compared with SR patients when receiving induction therapy with VTD while no differences were observed when receiving a lenalidomide containing regimen.
期刊介绍：
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
